TMPO and neoplasm: We injected ASOs against TMPO-AS1 optimized in the in vitro study intratumorally into PDX-bearing BALB/c nude mice, which resulted in marked decreases in the tumor volume and tumor weight (Fig. 6a–c), suggesting the promising therapeutic potential of targeting TMPO-AS1.